Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071253 · ClinicalTrials.gov registry record · Phase 4
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT00071253 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 180 participants.
The verdict
NCT00071253, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.
Interventions
- DRUG Olanzapine
- DRUG Divalproex Sodium (Delayed-Release Tablets)
- DRUG Divalproex Sodium (Extended-Release Tablets)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071253
The ClinicalTrials.gov registry entry for NCT00071253 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Olanzapine is the first listed.
NCT00071253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071253 about?
NCT00071253 is a clinical study titled "Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness". The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.
What is the current status of trial NCT00071253?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00071253?
The interventions under investigation include: Olanzapine (DRUG), Divalproex Sodium (Delayed-Release Tablets) (DRUG), Divalproex Sodium (Extended-Release Tablets) (DRUG).
Who is sponsoring clinical trial NCT00071253?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.